

Robert Greene Sterne
Edward J. Kessler
Jorge A. Goldstein
David K.S. Cornwell
Robert W. Esmond
Tracy-Gene G. Durkin
Michele A. Cimbala
Michael B. Ray
Robert E. Sokohl
Eric K. Steffe
Michael Q. Lee
Steven R. Ludwig
John M. Covert
Linda E. Alcorn
Robert C. Millonig
Lawrence B. Bugaisky
Donald J. Featherstone
Michael V. Messinger

Judith U. Kim
Timothy J. Shea, Jr.
Patrick E. Garrett
Jeffery T. Helvey
Heidi L. Kraus
Crystal D. Sayles
Edward W. Yee
Albert L. Ferro
Donald R. Banowitz
Peter A. Jackman
Molly A. McCall
Teresa U. Medler
Jeffrey S. Weaver
Kendrick P. Patterson
Vincent L. Capuano
Albert J. Fasulo II
Eldora Ellison Floyd
W. Russell Swindell

Thomas C. Fiala
Brian J. Del Buono
Virgil Lee Beaston
Reginald D. Lucas
Kimberly N. Reddick
Theodore A. Wood
Elizabeth J. Haanes
Bruce E. Chalker
Joseph S. Ostroff
Frank R. Cottingham
Christine M. Lhulier
Rae Lynn Prengaman
Jane Shershenovich
Lawrence J. Carroll
George S. Bardmesser
Rodney G. Maze

Registered Patent Agents*
Karen R. Markowicz
Andrea J. Kamagie
Nancy J. Leith
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longworth
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Matvenko
Mary B. Tung
Katrina Y. Pei
Bryan L. Skelton
Robert A. Schwartzman
Jason D. Eisenberg
John J. Figueroa

Senior Counsel
Samuel L. Fox
Kenneth C. Bass III
Lisa A. Dunner

*Admitted only in Maryland
*Admitted only in Virginia
*Admitted only in Texas
*Practice Limited to
Federal Agencies

August 19, 2002

Commissioner for Patents
Washington, D.C. 20231

Re: U.S. Utility Patent Appl. No. 10/005,647; Filed: December 7, 2001
For: **Glucuronyl C5-Epimerase, DNA Encoding
the Same and Uses Thereof**
Inventors: Jalkanen *et al.*
Our Ref: 1708.0280002/MAC/MBT

Sir:

Transmitted herewith for appropriate action are the following documents:

1. First Supplemental Information Disclosure Statement;
2. Form PTO-1449 (1 sheet citing 6 documents);
3. 6 documents attached cited in Form PTO-1449; and
4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Michele A. Cimbala

Michele A. Cimbala
Attorney for Applicants
Registration No. 33,851

MAC/MBT/lam
Enclosures

SKGF_DC1:17335.1

Sterne, Kessler, Goldstein & Fox P.L.L.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

WRITER'S DIRECT NUMBER:
(202) 371-2544
INTERNET ADDRESS:
MCIMBALA@SKGF.COM

RECEIVED
AUG 21 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


In re application of:

Jalkanen *et al.*

Appl. No. 10/005,647

Filed: December 7, 2001

For: **Glucuronyl C5-Epimerase Encoding
the Same and Uses Thereof**



Confirmation No. 9088

Art Unit: 1645

Examiner: *To be assigned*

Atty. Docket: 1708.0280002

RECEIVED

AUG 21 2002

TECH CENTER 1600/2900

Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

The partial international search report for the corresponding PCT application is provided as document AT1.

WO 01/38507 A1 is in the Japanese language. This document was cited on the English language partial international search report that is attached as document AT1. It appears that the

subject matter is drawn to an *Arabidopsis* gene encoding a GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase-4-reductase, deletion, substitution, addition, or insertion variants and a process for producing GDP-L-fucose.


This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. It is believed that no fee is required. However, if it is determined that a fee is required, the U.S. Patent and Trademark Office is hereby authorized to charge the fee to our Deposit Account No. 19-0036.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.


Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Michele A. Cimbala
Attorney for Applicants
Registration No. 33,851

Date: 8/19/02
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

 FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1708.0280002/MAC/MBT	APPLICATION NO. 10/005,647
	APPLICANT Jalkanen et al.	
	FILING DATE December 7, 2001	RECEIVED AUG 21 2002 TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1	5,939,289	8/17/1999	Ertesvåg et al.			10/8/1993
	AB1	6,372,477 B1	4/16/2002	Jørsboe et al.			5/27/1998
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL1	WO 01/38507	5/31/2001	Japan			X Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	<u>1</u>	Crawford, B.E. et al., "Cloning, Golgi Localization, and Enzyme Activity of the Full-length Heparin/Heparan Sulfate-Glucuronic Acid C5-epimerase", <i>J. Biol. Chem.</i> 276:21538-21543, The American Society for Biochemistry and Molecular Biology, Inc. (June 2001).
AS	<u>1</u>	Li, J.P. et al., "Characterization of the D-Glucuronyl C5-epimerase Involved in the Biosynthesis of Heparin and Heparan Sulfate", <i>J. Biol. Chem.</i> 276:20069-20077, The American Society for Biochemistry and Molecular Biology, Inc. (June 2001).
AT	<u>1</u>	PCT Partial International Search Report for PCT/FI01/01068, filed December 7, 2001, Biotie Therapies Corp. (Search Report mailed August 1, 2002).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.